Gavreto (pralsetinib) and Retevmo (selpercatinib) are prescription medications used to treat RET-positive cancer. Both the medications have their own Co-pay Assistance Programs which are designed to help eligible patients with the out-of-pocket costs associated with their treatment. Learn more at the following links.
